Twist Bioscience Corporation (TWST)
TWST trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), period ending 2025-09-30, https://www.sec.gov/Archives/edgar/data/1581280/000158128025000025/0001581280-25-000025-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), period ending 2025-09-30.
Profile
| Field | Value |
|---|---|
| Ticker | TWST on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2018 |
| SEC CIK | 0001581280 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $376.6M |
| Net income | -$77.7M |
| Operating income | Not in SEC XBRL data |
| Net margin | -20.6% |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | Not in SEC XBRL data |
| Total assets | Not in SEC XBRL data |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 26.6× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B7 | 2026-08-19 |
| Latest annual report | 10-K | 2025-11-17 |
| Latest quarterly / interim | 10-Q | 2026-08-03 |
| Latest current report FORM 8-K | 8-K | 2026-08-19 |
| Latest proxy | DEF 14A | 2026-01-06 |
Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -4.7% |
| 1 month | +7.4% |
| 3 months | +62.6% |
| Year to date | +367.7% |
| 1 year | +392.2% |
| From 52-week high | -27.6% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| IBRX | ImmunityBio Inc. | $9.80 | -3.16% | $10.4B |
| PCVX | Vaxcyte Inc. | $66.80 | -5.45% | $10.5B |
| KRYS | Krystal Biotech Inc. | $321.16 | -3.29% | $9.5B |
| QGEN | Qiagen N.V. Common Shares | $45.44 | +0.29% | $9.4B |
| KYMR | Kymera Therapeutics Inc. | $106.68 | -4.82% | $8.9B |
| TECH | Bio-Techne Corp | $72.48 | -0.11% | $11.4B |
| RGEN | Repligen Corporation | $175.42 | +1.69% | $8.6B |
| HALO | Halozyme Therapeutics Inc. | $109.62 | -1.31% | $12.4B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier